{"id":"ae84a9e7b414","type":"article","url":"https://hartvaat.nl/2026/03/07/aldosteronsynthaseremming-bij-resistente-hypertensie-beloften-en-onzekerheden/","title":"Aldosteronsynthaseremming bij resistente hypertensie: beloften en onzekerheden","title_en":"Aldosterone synthase inhibition in resistant hypertension: promises and unknowns","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts","internist"],"tags":["aldosteronsynthaseremmers","aprocitentan","bax24-trial","baxdrostat","bloeddrukbehandeling","eplerenon","lorundrostat","precision-trial","renale-denervatie","resistente-hypertensie","resistente-hypertensie-aldosteronremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00253-9/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00253-9/fulltext","authors":["Felix Mahfoud","Lucas Lauder"],"significance":7,"published":"2026-03-20","source_date":"2026-03-07","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This Lancet commentary discussed the promises and unknowns of aldosterone synthase inhibition for resistant hypertension, evaluating the therapeutic potential and remaining questions for this novel drug class.","created":"2026-07-03T10:32:36Z","updated":"2026-07-03T18:39:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit Lancet-commentaar bespreekt de potentie van aldosteronsynthaseremming als nieuwe therapie voor resistente hypertensie, die tot 20% van de hypertensiepatiënten treft. De auteurs wegen de veelbelovende resultaten af tegen de nog openstaande vragen over langetermijnveiligheid en cardiovasculaire eindpunten.","abstract_original":"Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide, affecting an estimated 1·3 billion adults.1 Although most patients achieve adequate blood pressure control with two or three antihypertensive agents, up to 20% of cases remain uncontrolled, despite guideline-recommended combination therapy. After exclusion of pseudo-resistance, these patients are classified as having true resistant hypertension, a phenotype associated with elevated cardiovascular risk and a higher prevalence of secondary hypertension."}